Blogs
Roche Holdings CEO Discusses Q3 2010 Results - Earnings Call Transcript -- Seeking Alpha
<p>Roche Holdings AG Basel (<a href='http://seekingalpha.com/symbol/rhhby.pk' title='Roche Holdings AG Basel'>RHHBY.PK</a>)</p><p>Q3 2010 Earnings Call</p><p>October 14, 2010 8:00 am ET</p><br/><a
Cancer treatment controls macular edema related to diabetes and to cataract surgery | Science Blog
Science Blog: Treating DMME with bevacizumab (Avastin), an anti-vascular endothelial growth factor (anti-VEGF) medication that inhibits abnormal blood vessels, was studied in115 patients (139 eyes) by the Pan-American Collaborative Retina Study Group, led by J. Fernando Arevalo, MD, of the Caracas
View From ASCO: Cancer Advances Made in Baby Steps « WebMD Newsroom
WebMD's editorial staff on the latest news from the world of health.
Can Array BioPharma Attract Yet Another Partner? -- Seeking Alpha
<strong><a href='http://biomedreports.com/'>M.E. Garza</a>submits:</strong><p><em>By Patrick Crutcher</em></p><p>Shares of Array BioPharma Inc.(NASDAQ:<a href='http://seekingalpha.com/symbol/arry' title='Array Biopharma Inc.'>ARRY</a>) traded up after announcing positive interim results of its
Array Biopharma: A Wall Street Anomaly -- Seeking Alpha
<strong>Ohad Hammer submits:</strong><p><span>Array’s (<a href='http://seekingalpha.com/symbol/arry' title='Array Biopharma Inc.'>ARRY</a>) shares keep on fluctuating in the $2.5-$3.5 range, relatively unchanged from the beginning of 2010. It seems that the market is having trouble assessing
Another Setback for Roche's Cancer Drug -- Seeking Alpha
<strong><a href='http://www.burrillreport.com/'>The Burrill Report</a>submits:</strong><p><em>By Michael Fitzhugh<br></em></p><p>Avastin, Roche's (<a href='http://seekingalpha.com/symbol/rhhby.pk' title='Roche Holdings AG Basel'>RHHBY.PK</a>) phenomenally successful advanced cancer medicine, did
Roche: Another Avastin Setback -- Seeking Alpha
<strong><a href='http://www.burrillreport.com/'>The Burrill Report</a>submits:</strong><p><em><br></em></p><p><em>By Michael Fitzhugh</em></p><p>Avastin, Roche's (<a href='http://seekingalpha.com/symbol/rhhby.pk' title='Roche Holdings AG Basel'>RHHBY.PK</a>) phenomenally successful advanced cancer
A Look at Immunogen Beyond the T-DM1 Setback -- Seeking Alpha
<strong>Ohad Hammer submits:</strong><p>The FDA’s decision to reject Roche’s (<a href='http://seekingalpha.com/symbol/rhhby.pk' alt='Roche Holdings AG Basel' title='Roche Holdings AG Basel'>RHHBY.PK</a>) filing for accelerated approval of T-DM1 had quite an impact on Immunogen’s
Immunogen: What Really Happened With T-DM1’s Filing? -- Seeking Alpha
<strong>Ohad Hammer submits:</strong><p>Last week, Roche (<a href='http://seekingalpha.com/symbol/rhhby.pk' alt='Roche Holdings AG Basel' title='Roche Holdings AG Basel'>RHHBY.PK</a>) announced that the FDA was unwilling to accept T-DM1’s accelerated approval filing for breast cancer, sending
Ziopharm Oncology: Place Your Bets -- Seeking Alpha
<strong>Wall Street Teacher submits:</strong><p><strong><a href="http://static.seekingalpha.com/uploads/2010/8/27/saupload_getchart_4.png" rel="lightbox"><img src="http://static.seekingalpha.com/uploads/2010/8/27/saupload_getchart_4_thumb2.png" align="right" hspace="6" vspace="6" /></a>Ziopharm
Refine by Content Type:
Refine by Source:
- seekingalpha.com (58)
- blogs.webmd.com (11)
- www.scienceblog.com (1)
